ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Arrowhead price target raised to $80 from $60 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...
Arrowhead: The Sarepta Partnership Validates RNAi Platform And Reduces Risk
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Arrowhead Pharma, Sarepta TX ink new gene therapy deal
Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...
Sarepta price target lowered to $75 from $80 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...
Stocktwits on MSN6d
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz Strong
Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...
Investing6d
Sarepta stock rated Overweight after Arrowhead acquisition
The revision follows Sarepta's announcement of a major collaboration with Arrowhead Pharmaceuticals (NASDAQ:ARWR) that significantly expands its product pipeline. Sarepta Therapeutics disclosed ...
Arrowhead Stock Rockets 16% After Major Licensing Deal
Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...
Investing6d
Arrowhead stock steadied by Sarepta deal, but Citi trims outlook
In other recent news, Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a transformative fiscal year, marked by a significant collaboration with Sarepta Therapeutics (NASDAQ:SRPT) and progress in ...
Investor's Business Daily on MSN6d
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
Investing6d
Sarepta stock rated Overweight after Arrowhead acquisition
The revision follows Sarepta's announcement of a major collaboration with Arrowhead Pharmaceuticals (NASDAQ:ARWR) that significantly expands its product pipeline. Sarepta Therapeutics disclosed its ...